» Articles » PMID: 22679342

Screening for Prostate Cancer Using Multivariate Mixed-effects Models

Overview
Journal J Appl Stat
Specialty Public Health
Date 2012 Jun 9
PMID 22679342
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Using several variables known to be related to prostate cancer, a multivariate classification method is developed to predict the onset of clinical prostate cancer. A multivariate mixed-effects model is used to describe longitudinal changes in prostate specific antigen (PSA), a free testosterone index (FTI), and body mass index (BMI) before any clinical evidence of prostate cancer. The patterns of change in these three variables are allowed to vary depending on whether the subject develops prostate cancer or not and the severity of the prostate cancer at diagnosis. An application of Bayes' theorem provides posterior probabilities that we use to predict whether an individual will develop prostate cancer and, if so, whether it is a high-risk or a low-risk cancer. The classification rule is applied sequentially one multivariate observation at a time until the subject is classified as a cancer case or until the last observation has been used. We perform the analyses using each of the three variables individually, combined together in pairs, and all three variables together in one analysis. We compare the classification results among the various analyses and a simulation study demonstrates how the sensitivity of prediction changes with respect to the number and type of variables used in the prediction process.

Citing Articles

EffUnet-SpaGen: An Efficient and Spatial Generative Approach to Glaucoma Detection.

Krishna Adithya V, Williams B, Czanner S, Kavitha S, Friedman D, Willoughby C J Imaging. 2024; 7(6).

PMID: 39080880 PMC: 8321378. DOI: 10.3390/jimaging7060092.


Repeated measures discriminant analysis using multivariate generalized estimation equations.

Brobbey A, Wiebe S, Nettel-Aguirre A, Josephson C, Williamson T, Lix L Stat Methods Med Res. 2021; 31(4):646-657.

PMID: 34898331 PMC: 8961244. DOI: 10.1177/09622802211032705.


A population-based study to develop juvenile arthritis case definitions for administrative health data using model-based dynamic classification.

Feely A, Lim L, Jiang D, Lix L BMC Med Res Methodol. 2021; 21(1):105.

PMID: 33993875 PMC: 8127203. DOI: 10.1186/s12874-021-01296-9.


Associations of specific-age and decade recall body mass index trajectories with obesity-related cancer.

Watson C, Renehan A, Geifman N BMC Cancer. 2021; 21(1):502.

PMID: 33952200 PMC: 8097878. DOI: 10.1186/s12885-021-08226-4.


The effect of random-effects misspecification on classification accuracy.

El Saeiti R, Garcia-Finana M, Hughes D Int J Biostat. 2021; 18(1):279-292.

PMID: 33770823 PMC: 9156334. DOI: 10.1515/ijb-2019-0159.


References
1.
Pauler D, Finkelstein D . Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes. Stat Med. 2002; 21(24):3897-911. DOI: 10.1002/sim.1392. View

2.
Carter H, Pearson J . Evaluation of changes in PSA in the management of men with prostate cancer. Semin Oncol. 1994; 21(5):554-9. View

3.
Kane C, Bassett W, Sadetsky N, Silva S, Wallace K, Pasta D . Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol. 2005; 173(3):732-6. DOI: 10.1097/01.ju.0000152408.25738.23. View

4.
Giovannucci E, Rimm E, Liu Y, Leitzmann M, Wu K, Stampfer M . Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst. 2003; 95(16):1240-4. DOI: 10.1093/jnci/djg009. View

5.
DAmico A, Whittington R, Malkowicz S, Weinstein M, Tomaszewski J, Schultz D . Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol. 2001; 166(6):2185-8. View